Optimization of natural killer T cell-mediated immunotherapy in cancer using cell-based and nanovector vaccines

Cancer Research

Volumn 74, Issue 6, 2014, Pages 1632-1638

  Faveeuw, C ^a,b,c,d,e   Trottein, F ^a,b,c,d,e  

^a INSTITUT PASTEUR DE LILLE   (France)

^b Institut National de la Santé et Recherche Médicale   (France)

^c INSERM U1019   (France)

^d UNIV LILLE   (France)

^e Institut Federatif de Recherche 114   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CANCER VACCINE; GLYCOLIPID; GLYCOLIPID ANTIGEN; NANOCARRIER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL THERAPY; DRUG DELIVERY SYSTEM; HUMAN; INNATE IMMUNITY; NATURAL KILLER T CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; GALACTOSYLCERAMIDES; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; NANOCAPSULES; NATURAL KILLER T-CELLS; NEOPLASMS;

EID: 84896503197     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3504     Document Type: Review

References (47)

1. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009;9: 28-38.
2. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, et al. Natural killer T cell ligand alphagalactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 2002;195:617-24. (Pubitemid 34461506)
3. Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, Salio M, et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest 2004;114: 1800-11. (Pubitemid 40385536)
4. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 2013;13:101-17.
5. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011;11:131-42.
6. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995;7:529-34. (Pubitemid 26077987)
7. Dhodapkar MV, Richter J. Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. Clin Immunol 2011;140: 160-66.
8. Exley MA, Nakayama T. NKT-cell-based immunotherapies in clinical trials. Clin Immunol 2011;140:117-18.
9. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, et al. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alphagalactosylceramide. Blood 2002;99:1259-66. (Pubitemid 34547079)
10. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002;8:3702-09. (Pubitemid 35424759)
11. Konishi J, Yamazaki K, Yokouchi H, Shinagawa N, Iwabuchi K, Nishimura M. The characteristics of human NKT cells in lung cancer-CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients. Hum Immunol 2004;65:1377-88. (Pubitemid 39539204)
12. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR, et al. Glycolipid antigen induces long-Term natural killer T cell anergy in mice. J Clin Invest 2005;115:2572-83. (Pubitemid 41266220)
13. Chang DH,Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005;201:1503-17. (Pubitemid 40664093)
14. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFNgamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 2002;3:867-74.
15. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004;103:383-89. (Pubitemid 38140063)
16. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 1999;163: 2387-91. (Pubitemid 29399156)
17. Motohashi S, Okamoto Y, Yoshino I, Nakayama T. Anti-Tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin Immunol 2011;140:167-76.
18. Richter J, Neparidze N, Zhang L, Nair S, Monesmith T, Sundaram R, et al. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 2013;121:423-30.
19. Dellabona P, Casorati G, de Lalla C, Montagna D, Locatelli F. On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies. Clin Immunol 2011;140: 152-59.
20. Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, Yamamoto S, et al. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci 2009;100:1092-98.
21. Sun W, Subrahmanyam PB, East JE, Webb TJ. Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells. J Interferon Cytokine Res 2012;32:505-16.
22. Barral P, Polzella P, Bruckbauer A, van Rooijen N, Besra GS, Cerundolo V, et al. CD169(+) macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nat Immunol 2010;11:303-12.
23. Barral P, Sanchez-Nino MD, van Rooijen N, Cerundolo V, Batista FD. The location of splenic NKT cells favours their rapid activation by blood-borne antigen. Embo J 2012;31:2378-90.
24. Macho Fernandez E, Chang J, Fontaine J, Bialecki E, Rodriguez F, Werkmeister E, et al. Activation of invariant Natural Killer T lymphocytes in response to the alpha-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles. Int J Pharm 2012;423:45-54.
25. Thapa P, Zhang G, Xia C, Gelbard A, Overwijk WW, Liu C, et al. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine 2009;27:3484-88.
26. Nakamura T, Yamazaki D, Yamauchi J, Harashima H. The nanoparticulation by octaarginine-modified liposome improves alpha-galactosylceramide-mediated antitumor therapy via systemic administration. J Control Release 2013;171:216-24.
27. Ishii M, Kojima N. Effective stimulation of invariant natural killer T cells by oligomannose-coated liposomes. Int Immunopharmacol 2013;15: 685-92.
28. Kawasaki N, Vela JL, Nycholat CM, Rademacher C, Khurana A, van Rooijen N, et al. Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation. Proc Natl Acad Sci U S A 2013;110: 7826-31.
29. Semmling V, Lukacs-Kornek V, Thaiss CA, Quast T, Hochheiser K, Panzer U, et al. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol 2010;11:313-20.
30. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, et al. Human CD141+ (BDCA-3) +dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010;207:1247-60.
31. Shortman K, Heath WR. The CD8+ dendritic cell subset. Immunol Rev 2010;234:18-31.
32. Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY, et al. A combination of chemoimmunotherapies can efficiently break selftolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 2007;67:7477-86.
33. Fukushima S, Hirata S, Motomura Y, Fukuma D, Matsunaga Y, Ikuta Y, et al. Multiple antigen-Targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells. J Immunother 2009;32:219-31.
34. Matsuyoshi H, Hirata S, Yoshitake Y, Motomura Y, Fukuma D, Kurisaki A, et al. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells. Cancer Sci 2005;96:889-96. (Pubitemid 43056128)
35. Zeng J, Shahbazi M, Wu C, Toh HC, Wang S. Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression. J Immunol 2012;188:4297-4304.
36. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S. Crosspresentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 2007;204:2641-53. (Pubitemid 350063944)
37. Hong S, Lee H, Jung K, Lee SM, Lee SJ, Jun HJ, et al. Tumor cells loaded with alpha-galactosylceramide promote therapeutic NKTdependent anti-Tumor immunity in multiple myeloma. Immunol Lett 2013;156:132-39.
38. Hunn MK, Farrand KJ, Broadley KW, Weinkove R, Ferguson P, Miller RJ, et al. Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma. Clin Cancer Res 2012;18:6446-59.
39. Mattarollo SR, West AC, Steegh K, Duret H, Paget C, Martin B, et al. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood 2012;120: 3019-29.
40. Mattarollo SR, Steegh K, Li M, Duret H, Foong Ngiow S, Smyth MJ. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. Immunol Cell Biol 2013;91:105-14.
41. Fujii S, Goto A, Shimizu K. Antigen mRNA-Transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity. Blood 2009;113:4262-72.
42. Fujii SI, Shimizu K. Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response. Oncoimmunology 2013;2:e23432.
43. Shimizu K, Mizuno T, Shinga J, Asakura M, Kakimi K, Ishii Y, et al. Vaccination with antigen-Transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells. Cancer Res 2013;73:62-73.
44. Kim YJ, Ko HJ, Kim YS, Kim DH, Kang S, Kim JM, et al. alpha-Galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity. Int J Cancer 2008;122: 2774-83. (Pubitemid 351631380)
45. Stirnemann K, Romero JF, Baldi L, Robert B, Cesson V, Besra GS, et al. Sustained activation and tumor targeting of NKT cells using a CD1danti-HER2-scFv fusion protein induce antitumor effects in mice. J Clin Invest 2008;118:994-1005. (Pubitemid 351364607)
46. McKee SJ, Young VL, Clow F, Hayman CM, Baird MA, Hermans IF, et al. Virus-like particles and alpha-galactosylceramide form a selfadjuvanting composite particle that elicits anti-Tumor responses. J Control Release 2012;159:338-45.
47. Gehrmann U, Hiltbrunner S, Georgoudaki AM, Karlsson MC, Naslund TI, Gabrielsson S. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with alpha-galactosylceramide on exosomes. Cancer Res 2013;73:3865-76.